Trial Profile
A Multi-center, Randomized, Sham-controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in Subjects With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs SBI 101 (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions
- Sponsors Sentien Biotechnologies
- 15 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 15 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 30 Jul 2020 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.